Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 382

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1A
Chunk 382
---
 best interest of our company
or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate
or seek some other non-litigious action or solution.

Because many of the patents we own are owned by our subsidiaries
and investments, and in certain cases by subsidiaries or investments that are not or will not be directly commercializing products, we
may not be in a position to obtain a permanent injunction against a third party that is found to infringe our patents.

Many patents that we own are assigned to our subsidiaries or investment
companies. If a third party is found to be infringing such patents, we and our direct subsidiaries may not be able to permanently enjoin
the third party from making, using, offering for sale or selling the infringing product or activity for the remaining life of such patent
in the United States or other jurisdictions when the patent is assigned to a subsidiary, which is not the entity that is or would
be commercializing a potentially competitive product or service. In such a circumstance, such third party may be able to compete with
us or our subsidiaries or investment companies, which could have a material adverse effect on our competitive position, business, financial
condition, results of operations, and prospects.

Changes in U.S. patent law or the patent law of other countries
or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.

As is the case with other biopharmaceutical companies, the Company’s
success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical
industry involves both technological and legal complexity and is costly, time-consuming and inherently uncertain. For example, on
September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act
included a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be
prosecuted and that may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned
in March 2013 to a “first to file” system in which the first inventor to file a patent application is typically entitled
to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO, and may become